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Abstract
BACKGROUND: Although the importance of lymphatic function is well recognized, the lack of real-time imaging mo-
dalities limits our understanding of its role in many diseases. In a phase 0 exploratory study, we used dynamic, near-
infrared (NIR) fluorescence imaging to assess the extremes of lymphatic architecture and transport in healthy human
subjects and in subjects clinically diagnosedwith unilateral lymphedema (LE), a disease that can be prevalent in cancer
survivors.METHODS AND RESULTS: Active lymphatic propulsion was imaged after intradermal injections of 25 μg of
indocyanine green (total maximum dose≤400 μg) bilaterally in the arms or legs of control and subjects. Images show
well-defined lymphatic structures with propulsive dye transport in limbs of healthy subjects. In LE subjects, we
observed extravascular dye accumulation, networks of fluorescent lymphatic capillaries, and/or tortuous lymphatic ves-
sels in all symptomatic and some asymptomatic limbs. Statistical models indicate that disease status and/or limb sig-
nificantly affect parameters of apparent lymph propagation velocity and contractile frequency. CONCLUSIONS: These
clinical research studies demonstrate the potential of NIR fluorescence imaging as a diagnostic measure of functional
lymphatics and as a new tool in translational research studies to decipher the role of the lymphatic system in cancer
and other diseases.
Translational Oncology (2010) 3, 362–372
Introduction
The lymphatic system is composed of a network of capillaries, vessels,
trunks, ducts, and lymph nodes that collect fluid, macromolecules, pro-
teins, and immune cells from the interstitial space, transport the fluid or
lymph, and return it to the venous system [1]. Unlike the hemovascular
system, the lymphatics do not have a centralized pumping organ, and
lymph is transported through the lymphatics, primarily by cyclic con-
tractions of vessel subunits called lymphangions. Bounded by valves to
ensure unidirectional flow, lymphangions are arranged in series and se-
quentially contract to propel the lymph through the lymphatics in a
peristaltic manner [1]. Although contractile function is crucial to the
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transport of lymph, the fundamental physiological mechanisms govern-
ing this phenomenon are not well understood, and there are nomethods
to evaluate contractile function noninvasively in humans.
Disruption of lymph transport, because of impaired lymphatic func-
tion, reduced numbers of lymphatic vessels, valvular insufficiencies, or
exacerbated by combinations of the above results in the chronic condi-
tion of lymphedema (LE) and its sequelae of inflammatory response
results [2–4]. Treatment for LE is generally limited to compression ban-
daging and manual lymphatic drainage or massage to minimize swelling
and encourage lymph drainage. There is no cure for lymphedema.
In Western countries, acquired LE is generally caused by trauma or
surgery, typically after lymph node resection for cancer staging or ther-
apy. It is estimated that, depending on the therapeutic approach taken,
as many as 40% of all breast cancer patients who undergo axillary lymph
node dissection [5–7] and 64% of all cancer patients who undergo groin
lymph node dissection [8] encounter acquired LE. LE may present
weeks to years after trauma or surgery, often after a challenge to the im-
mune system. Although there are no means to predict who will develop
“secondary” LE and when, recent work suggests that causal or suscepti-
bility genes may be involved [9]. In contrast, hereditary or primary LE
has been associated, thus far, with mutations in vascular endothelial
growth factor receptor 3 [10,11] (Milroy or Miege disease), SOX18
[11], and FOXC2 [12–15] (lymphedema-distichiasis), in which the lat-
ter disease is noted for valvular insufficiencies and has been characterized
by lymphoscintigraphy as exhibiting lymph reflux in dilated lymphatic
vessels of the leg [13].
Currently, lymphoscintigraphy is the onlymeans available to routinely
image the lymphatics. Although gross lymph architecture such as main
vessels and nodes are visualized in scintigrams, the long integration times
associated with gamma cameras prevent imaging of real-time lymphatic
contractile function and the spatial resolution limits visualization of fine
lymphatic vasculature. Because the lymphatics provide little endogenous
contrast, direct imaging of the lymphatics is difficult and lymphatic archi-
tecture and function generally cannot be probed directly with ultrasound,
magnetic resonance, or computed tomography. In addition, the lym-
phatic vasculature is not readily accessible for administration of the milli-
liters of contrast agent needed for magnetic resonance or computed
tomography angiography, making aberrant lymph architecture difficult
to routinely assess (for reviews on lymphatic imaging, see Sharma et al.
[16], Szuba and Rockson [17], and Lucarelli et al. [18]). In an extensive
review, Marshall et al. [19] summarized the work of several groups who
have developed optical imaging devices for human lymphatic imaging
using near-infrared (NIR) fluorescence. In these studies, indocyanine
green (ICG), a green dye used for hepatic clearance and ophthalmological
indications, was used primarily to map the lymphatics and provide sur-
gical guidance for nodal resection. Although these optical imaging devices
are sensitive enough to image the lymphatics with milligram amounts of
ICG, none have quantified contractile lymphatic function [19–23]. Re-
cently, we demonstrated the feasibility for noninvasive imaging and
quantification of propulsive, contractile lymphatic function after intra-
dermal administration of microgram amounts of ICG [20,24].
The objective of the phase 0 clinical feasibility study described was
to evaluate the utility of NIR fluorescence to 1) image differences
within the lymphatic architecture and its contractile function and 2)
quantify the apparent propagation velocity and frequency or period
of contractile transport in the arms or legs of healthy control subjects
as well as of subjects clinically diagnosed with unilateral LE. The ability
to noninvasively visualize lymphatic architecture and quantify its pro-
pulsive function within asymptomatic and symptomatic limbs of sub-
jects with LE as well as within the limbs of healthy subjects provides the
first opportunity to investigate changes in lymphatic function with
human disease.
Materials and Methods
Study Design
The protocol used for this feasibility study was approved by the
US Food and Drug Administration under combinational exploratory
investigational new drug application 76,920 for the off-label use of ICG
as a NIR fluorescent contrast agent. The Health Insurance Portability
and Accountability Act (HIPAA)-compliant studies were approved by
the institutional review board at Baylor College ofMedicine inHouston,
Texas, where the study was conducted and by the institutional review
board at the University of Texas Health Science Center at Houston,
where the imaging data were evaluated. A total of 24 healthy volunteers
and 20 subjects diagnosed with stage 1 or 2 unilateral LEwere recruited
for this study. The summarized demographic data for all 44 subjects
imaged are presented in Table 1. The demographics, dosage, and dis-
ease cause for each subject are available in Tables W1, W2, W3, and
W4. Persons weighing more than 400 lb (weight limit of bed) or with
known sensitivity to iodinewere excluded from the study as wereminors
and pregnant or nursing women. Half of the LE subjects had been
clinically diagnosed with unilateral leg LE and half with unilateral arm
LE. In this phase 0 study, we did not control for cause of LE, that is,
whether acquired or primary; however, 3 of 10 leg LE subjects and 10
of 10 arm LE subjects were cancer survivors. Half of the healthy vol-
unteers and LE subjects received intradermal injections of ICG in both
arms and the remainder in both legs. Immediately after injection, all
subjects were imaged with a custom-built NIR fluorescence imaging
system [24]. Total imaging time varied from subject to subject, but
was typically 2 hours. Subjects were supine during imaging, and vital
signs were monitored for 2 hours after injections with follow-up calls
made 24 and 48 hours later. No adverse events were associated with
the drug or device in this feasibility study. Neither the effects of de-
mographics (e.g., sex, age, weight, and ethnicity) nor physiological
Table 1. Demographic Characteristics of Subjects Imaged.
Characteristic Healthy (n = 24) Lymphedema (n = 20)
Sex, n (%)
Male 5 (20.8) 1 (5.0)
Female 19 (79.2) 19 (95.0)
Age, mean ± SD,* years 38.2 ± 11.0 49.7 ± 17.6
Mean weight, kg ± SD* 72.7 ± 12.1 74.3 ± 21.3
Body surface area,† m2 ± SD* 1.8 ± 0.2 1.8 ± 0.2
Ethnicity, n (%)
Caucasian 19 (79.2) 15 (75.0)
Black 2 (8.3) 3 (15.0)
Asian 2 (8.3) 1 (5.0)
Hispanic 1 (4.2) 1 (5.0)
Other 0 (0.0) 0 (0.0)
Limb, n (%)
Leg 12 (50.0) 10 (50.0)
Arm 12 (50.0) 10 (50.0)
Cause of disease, n (%) Arms (n = 10) Legs (n = 10)
Primary — 0 (0.0) 3 (30.0)
After cancer treatment — 10 (100.0) 3 (30.0)
After injury — 0 (0.0) 2 (20.0)
Insect bite — 0 (0.0) 2 (20.0)
*SD indicates standard deviation.
†Body surface area calculated by the DuBois formula.
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factors contributing to lymphatic transport (e.g., pressure, stress) were
considered in this limited feasibility study.
Injection of Contrast Agent
ICG is a tricarbocyanine dye that is approved for hepatic, cardio-
vascular, and ophthalmology applications. It is typically administered
systemically in adults with the total dose not exceeding 2 mg/kg. On
administration, ICG associates to albumin and is subsequently taken
up by the liver and secreted into the bile. With a biologic half-life of
2 to 4 minutes in the blood, ICG has been used safely for more than
50 years [25]. The dye can be excited between 760 and 785 nm, and the
emitted fluorescent signal can be collected between 820 and 840 nm.
ICG exhibits a subnanosecond fluorescent lifetime, indicating the lack
of the existence of a triplet state and formation of damaging free radicals
on excitation.
For these studies, ICG was reconstituted in water to a base concen-
tration of 2.5 mg/ml and subsequently diluted with saline to achieve a
final concentration of 0.25mg/ml. Each subject received up to 16 intra-
dermal injections of 0.1 ml of diluted ICG for a maximum total dose of
400 μg. Injection sites varied owing to areas of fibrosis in LE subjects. In
the arms, four injections were administered between the digits of each
hand for a total dose of 200 μg of ICG, or when fibrosis made inter-
digital injection difficult, a total of six injections were made on each
arm, typically with two on the top of the hand, two on the medial fore-
arm, and two on the lateral forearm for a total dose of 300 μg of ICG.
Generally, eight injections were administered on each leg (two on top of
the foot, two on the medial ankle, one on the heel, two on the calf, and
one on the thigh) for a total dose of 400 μg of ICG. One LE leg subject
declined additional injections after two injections were administered for
a total dose of 50 μg. In all cases, the injection sites for individual sub-
jects matched between right and left limbs. Ten subjects requested use of
a topical anesthetic with lidocaine 2.5% and prilocaine 2.5% cream
applied directly to the injection site to lessen the injection sensation.
For this study, the clinically identified diseased limbs of unilateral LE
subjects are referred to as symptomatic, the clinically unaffected limbs
are referred to as asymptomatic, and all limbs of the controls subjects are
referred to as normal or control.
NIR Fluorescence Imaging
After intradermal injection, the injection sites were covered with
black vinyl tape to prevent camera oversaturation. The location and
movement of the ICG in each limb was then imaged simultaneously
using two custom-built fluorescence imaging systems (see Video W1
for transit of ICG immediately after administration). During the imag-
ing session, each imaging system was used to scan the lymphatics from
the injection sites near the digits to the draining nodal basin to visualize
the lymphatics of the entire limb. Occasionally, bilateral limbs were im-
aged with a single imaging system. Each system consists of a 785-nm
excitation light source, an NIR-sensitive image intensifier, and a cus-
tomized charge-coupled device (CCD) camera outfitted with filters
to collect fluorescence at 830 nm. After imaging the first eight control
subjects, the original 80-mW laser diode used to provide the 785-nm
excitation light source was replaced with a 500-mW laser diode to pro-
vide a broader, brighter, and more uniform illumination of the field of
view, resulting in sharper and more detailed fluorescent images. The
emitted excitation light was attenuated using an optical diffuser such
that a maximal tissue surface area of approximately 900 cm2 was illumi-
nated with less than 1.9 mW/cm2. Excitation light propagated through
tissues to activate the injected ICG. The generated fluorescent signal
that emanated from the tissues was filtered with a 785-nm holographic
notch filter (optical density ≥6) and an 830-nm band-pass filter (op-
tical density ≥4). A 28-mm Nikkor lens (Nikon, Melville, NY) was
used to focus the fluorescent signal onto the photocathode of a Gen 3
image intensifier. The intensified image was acquired with a customized,
16-bit, frame transfer, CCD camera. An exposure time of 200 milli-
seconds and a total acquisition time of ∼650 milliseconds per image
permitted near real-time imaging of the lymphatics in vivo and enabled
compilation of images to create movies. All supplemental videos (avail-
able online) are approximately three times faster than real time.
Quantification of Lymphatic Function
The two-dimensional fluorescent images were previewed using
ImageJ (National Institutes of Health, Bethesda, MD) to visually iden-
tify subsets of images containing lymphatic contractile function as
distinguished by the movement of “packets” of higher fluorescent in-
tensity along the lymphatic vessels from the regions of high dye
concentration near the injection sites to the regional nodal basin. A
custom MATLAB (MathWorks, Natick, MA) program was then used
to identify regions of interest (ROIs) along the length of the lymphatic
vessels and to calculate the apparent distance each fluorescent packet
traveled between ROIs. The distance is denoted as apparent to reflect
the lack of information in the third dimension. Apparent propagation
velocity was computed by dividing the apparent distance traveled by
the travel time of the fluorescent packet. In cases where fluorescence
was observed to move distally from the local draining lymphatic basin,
the apparent velocities were reported as negative. The period was mea-
sured as the time lapse between consecutive lymphatic propulsion
events in the same ROI. In this initial feasibility study, limbs were in-
terrogated by scanning the camera field of view across the entire limb.
Because we did not always observe consecutive pulsatile events, there
are fewer period measurements than velocity measurements. To ac-
count for the variable imaging time and the variable number of propul-
sion events observed in each limb, we computed the overall propulsion
rate for each subject by dividing the total number of observed packets
in each limb by the total time spent imaging that limb. Total imaging
time is the time difference between when the first image was taken and
when the last image was obtained.
Because ICG concentration, lymphatic vessel diameter and depth,
and skin pigmentation may not be expected to be constant across the
length of a lymphatic vessel, the re-emitted fluorescence may be ex-
pected to vary across the length of the vessel. As ICG-laden lymph is
propelled toward the draining lymph node basins, it is diluted by non
ICG-laden lymph collected from the initial collecting lymphatics lo-
cated away from the injection site. As lymphangions fill and empty
of ICG-laden lymph, their fluorescent intensity will also increase and
decrease with time. Because we measure the time rate of change of fluo-
rescence intensity at a single location to denote a “pulse,” spatial varia-
tions across the length of a vessel do not affect our quantitative values
of apparent velocity, period, or propulsion rate. All images presented
herein are in pseudocolor.
Statistical Analysis
Whereas this was a feasibility trial and therefore not powered for
statistics, we performed some statistical analyses to determine which
variables may affect the quantified data. R: A Language and Environment
for Statistical Computing [26] was used to model the effects of limb (arm
or leg), diagnosis (control, symptomatic, or asymptomatic), side (right
or left), dose of ICG, and topical anesthesia (with or without) for all
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values of apparent velocity and period as well as the effect of diagnosis,
limb, side, and dose on the overall propulsion rate. The lme4 package
in R was used to create linear models for these data, which included the
overall and the within subject effects of the factors. The factors were
considered significant if their inclusion in the model resulted in a sig-
nificantly better (P < .05) model fit than a model excluding them. Be-
cause of the distributions of these data and the presence of negative
values in the raw data, period and apparent velocity measures were
converted to ranks for modeling.
Results
Table 2 summarizes the quantified data by diagnosis and limb, includ-
ing the number of apparent propagation velocity and period measure-
ments, their ranges, medians, means and SDs, as well as the overall
propulsion rates. Tables W1, W2, W3, and W4 summarize 1) the
apparent velocities as determined from the movement of fluorescent
packets within the vessels because of lymphatic contractions, 2) the
period between consecutive contractile events, 3) the overall propul-
sion rates, and 4) pertinent comments for individual control and LE
subjects. For pooled measurements (n = 3423 for apparent velocity
and n = 1738 for period) of all 44 subjects in the study, our linear
models indicate that diagnosis (i.e., control, asymptomatic, or symp-
tomatic) has a significant effect on both the apparent propagation ve-
locity (P < .0005) and period (P < .005) and that limb (i.e., arm or
leg) has a significant effect on the period (P < .01) but not apparent
velocity. The models indicate no significant effect on the apparent
propagation velocity or period due to side (i.e., left or right), dose,
or the application of local, topical anesthetic. The data from 10 sub-
jects who received topical anesthetic comprised 739 of the total 3423
values of apparent velocity and 361 of the total 1738 values of period.
Monte Carlo simulation, using the available data as a model, demon-
strated sufficient power to detect a significant effect of the topical
anesthetic on apparent propagation velocity or period had one existed,
at a P value of less than 0.05 and a power greater than 80%. In the
following, we focus on lymphatic architecture and the quantification
of lymphatic transport due to contractile function in control limbs as
well as in the limbs of subjects with clinically diagnosed unilateral LE.
Specific cases presented below reference subject identification codes
found in Tables W1, W2, W3, and W4.
Control Arms
Although the number and anatomic map of lymphatic vessels varied
between control subjects, the lymphatic structure generally consisted
of well-defined channels as illustrated in Figure 1. Figure 1A shows
the web of lymphatic vessels in the dorsal left hand after four interdigital
injections of ICG; Figure 1B shows the lymphatic vasculature in the
medial right elbow; and Figure 1, C and D, shows the lymph vessels
in the upper and entire right arm, respectively. Active contractile func-
tion with propagation toward the axilla, as shown in Video W2, was
observed in all control arms. However, contractile function was not
observed in every fluorescent vessel. Axillary and cubital lymph nodes
were observed in some subjects.
Figure 2 illustrates the fluorescent intensity profiles as a function
of time for two ROIs along a lymphatic vessel in the medial arm
(Figure 2A). As the packet propagates through each ROI, a peak in
fluorescent intensity is observed. Figure 2B shows that ROI 1 (blue)
fills and empties its contents into ROI 2 (red). The apparent propa-
gation velocity is calculated by dividing the apparent distance between
ROIs 1 and 2 by time difference between the corresponding inten-
sity peaks, whereas the period is defined by the time lapse between
successive intensity peaks in the same ROI. The mean ± SD appar-
ent propagation velocity and period measured in the control arms was
0.8 ± 0.4 cm/sec and 48.2 ± 36.8 seconds, respectively, as shown in
Table 2. The mean ± SD propulsion rate, defined by the total num-
ber of propulsion events (i.e., velocity measurements) divided by the
total time imaged, is 1.3 ± 1.2 propulsions per minute, as also shown
in Table 2.
Control Legs
Similar to that of arms, the lymphatic architecture in the legs also
varied between control subjects, but generally consisted of well-defined
structures as illustrated in Figure 3. Figure 3A illustrates the web of
lymphatics in the dorsum of the left foot after two injections of ICG
approximately one inch above the digits (see Video W3 for visualiza-
tion of lymphatic flow in the foot). In Figure 3B, the lymphatics located
in the medial right leg are shown; in Figure 3C , two lymphatic vessels
are visible in the right patellar fossa; and in Figure 3D, deep lymphatics
vessels draining toward the inguinal lymph node basin in the left leg
are shown. Lymphatic vessels located deep within the leg appear dif-
fuse owing to the scatter of light from intervening tissues. In five subjects
(indicated in Tables W1 and W2), tortuous lymphatic vessels were
also seen. In one control limb, a small area of extravascular dye was
observed near an injection site, whereas several smaller vessels were
observed radiating from an injection site another control limb. Lym-
phatic reflux or retrograde propagation of fluorescent packets toward
the feet was observed in three control subjects. As shown in Table 2,
the mean ± SD apparent propagation velocity in the legs was 0.9 ±
0.7 cm/sec, the mean ± SD period was 52.2 ± 36.1 seconds, and the
overall propulsion rate was 0.4 ± 0.3 propulsions per minute. Inguinal
and popliteal nodes were observed in some subjects.
Asymptomatic and Symptomatic Arms
The lymphatic architecture in LE subjects was markedly different
than that in control subjects and was consistent with that seen by Unno
Table 2. Summary of Apparent Contractile Propagation Velocities and Periods.
Limb No. Limbs No. Velocity
Measurements
Range
(cm/sec)
Median
(cm/sec)
Mean ± SD
(cm/sec)
No. Period
Measurements
Range (sec) Median
(sec)
Mean ± SD
(sec)
Overall Propulsion Rate
(Propulsions per Minute)
Control arm 24 1493 0.07 to 4.9 0.7 0.8 ± 0.4 803 2.3-250.5 34.6 48.2 ± 36.8 1.3 ± 1.2
Asymptomatic arm 10 731 −1.2 to 4.9 0.7 0.8 ± 0.4 402 2.8-200.0 29.9 39.7 ± 29.1 1.2 ± 1.0
Symptomatic arm 10 138 −4.2 to 4.1 0.7 0.7 ± 1.0 97 5.0-84.0 24.4 32.1 ± 17.9 0.3 ± 0.3
Control leg 24 734 −1.5 to 11.7 0.8 0.9 ± 0.7 273 3.2-193.8 43.2 52.2 ± 36.1 0.4 ± 0.3
Asymptomatic leg 10 194 0.1 to 2.7 0.7 0.8 ± 0.5 91 12.4-252.0 50.1 65.3 ± 46.4 0.3 ± 0.2
Symptomatic leg 10 133 0.1 to 1.9 0.7 0.8 ± 0.4 72 6.0-228.3 64.0 72.1 ± 45.1 0.2 ± 0.2
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et al. [22]. Architectural abnormalities such as regions of diffused dye
patterns arising from extravascular fluorescence and dense networks of
capillary lymphatics were not typically observed in control subjects. Al-
though tortuous vessels were observed in 5 of 48 control limbs, they were
seen in nearly half of the 40 asymptomatic and symptomatic limbs (arms
and legs).
Figure 4 illustrates symptomatic and asymptomatic hands and arms of
typical subjects with acquired LE after breast cancer treatment. Figure 4A
Figure 1. Images of lymphatics of control arm subjects: (A) left hand after interdigital injections (subject CA08), (B) right elbow (subject
CA10, Video W1 shows typical lymphatic flow), (C) upper right arm (subject CA12), and (D) entire right arm from wrist to shoulder (subject
CA12). Black spots are covered injection sites.
Figure 2. Quantitation of lymphatic function. Lymphatic function is quantified by analyzing the profiles of fluorescent intensity at two
ROIs (A) on a medial arm of subject CA10. (B) The three-dimensional plot of fluorescent intensity as a function of time and distance
illustrates the propagation of the fluorescent packet along the vessel. The distance traveled is defined as the distance between ROIs 1
and 2 in (A) and the transit time (ΔtTransit) is defined as the time lapse between corresponding intensity peaks in ROIs 1 and 2 as illus-
trated in (C). Period is the time lapse between successive peaks in the same ROI.
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shows extravascular fluorescence just above and below the wrist with
a conducting lymphatic channel connecting the two areas, whereas
the asymptomatic hand has well-defined lymphatic architecture (Fig-
ure 4B). In Figure 4C , the medial view of a symptomatic elbow exhib-
ited extravascular fluorescence and tortuous vessels, but only a single
lymphatic vessel was observed on the asymptomatic arm (Figure 4D).
One subject, who underwent bilateral mastectomies 9 years apart and
developed clinically diagnosed unilateral right arm LE approximately
1 year before the second (left breast) mastectomy, is noteworthy. Her
right, symptomatic arm had extravascular fluorescence throughout the
entire arm (Figure 4E), whereas the left, clinically unremarkable asymp-
tomatic arm had two areas of fluorescent lymphatic capillaries with tor-
tuous vessels near the wrist and upper arm (Figure 4F [see Figure W1
for magnified images of abnormalities]) as well as backward propagation
of fluorescence in the main lymphatic channel just above the wrist.
Another noteworthy case is that of a postmastectomy subject who had
active backward propulsion of fluorescence into her hand and fingers
as evidenced by the bright fluorescent signal emanating from her hand
(Figure 4G). Incidentally, a spontaneous fistula or “weep hole” had de-
veloped in her palm (Figure 4H ) from which, as reported by the sub-
ject, fluid leaked periodically. Interestingly, manual lymphatic drainage
therapy did not mitigate her LE.
Figure 5A shows a closer view of a lymphatic vessel with apparent
backward propagation of fluorescent packets in the asymptomatic limb
previously shown in Figure 4F (see Video W4 for visualization). Fig-
ure 5B shows a three-dimensional plot of the fluorescent intensity as
a function of time and distance traveled along the lymphatic vessel.
By tracking the appearance of the “peaks” of fluorescence, the forward
and subsequent retrograde propagation of each fluorescent packet can
be identified. Figure 5C shows the fluorescent intensity profiles for two
ROIs (Figure 5A) located 8 cm apart.
While active contractile transport was observed in every asymp-
tomatic arm of persons with LE, only three propulsion events were ob-
served in two asymptomatic arms, whereas two or fewer propulsion
events were seen in six symptomatic limbs. As shown in Table 2, the
mean ± SD apparent velocities in the symptomatic and asymptom-
atic arms were 0.7 ± 1.0 and 0.8 ± 0.4 cm/sec, respectively, and the
mean ± SD periods were 32.1 ± 17.9 and 39.7 ± 29.1 seconds, respec-
tively. On average, 60 ± 76 more packets were seen in the asymptomatic
arms than the contralateral symptomatic limbs. The overall propul-
sion rates were 1.2 ± 1.0 and 0.3 ± 0.3 propulsions per minute for the
asymptomatic and symptomatic arms, respectively, as shown in Table 2.
Retrograde propagation of fluorescence was observed in the arms of
two subjects with LE.
Asymptomatic and Symptomatic Legs
Many of the lymphatic architectural features seen in symptomatic
and asymptomatic arms also occurred in leg LE. As an example, Fig-
ure 6A indicates extensive extravascular fluorescence over much of the
symptomatic leg, whereas the asymptomatic leg appears to have few
but well-defined lymphatics vessels. However, a closer examination of
the ankles of the same subject (Figure 6B; see Figure W2 for magni-
fied images) reveals an abnormal tortuous lymphatic vessel draining
from the injection site toward the bottom of the asymptomatic foot,
Figure 3. Images of lymphatics of control leg subjects: (A) left foot (subject CL09, Video W2 shows typical lymphatic flow), (B) lower leg
(subject CL08), (C) back of knee (subject CL12), and (D) thigh (subject CL03).
Translational Oncology Vol. 3, No. 6, 2010 NIR Fluorescence Imaging of Human Lymphatics Rasmussen et al. 367
Figure 4. Comparison of lymphatic architecture in symptomatic and asymptomatic arms. (A, C, and E) present images of the symptomatic
arm, whereas (B, D, and F) present images of the contralateral asymptomatic arms of three subjects. (A) Symptomatic hand with extra-
vascular fluorescence from injection sites and some networks of fluorescent lymphatic capillaries and (B) normal-looking asymptomatic
hand (subject LA06). (C) Symptomatic arm with extravascular fluorescence and tortuous vessels and (D) normal-looking asymptomatic arm
(subject LA08). (E) Symptomatic arm with extravascular fluorescence and (F) asymptomatic arm with fluorescent lymphatic capillaries,
tortuous lymph vessels, and lymph reflux (subject LA03; Figure 6). (G) Back and (H) front of symptomatic hand in which active lymphatic
propulsion was seen pushing fluid into hand (subject LA01). Bright spot on palm (H) is a spontaneous fistula or weep hole that developed
to permit lymph to drain.
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although no fluorescence is visible in the sole of the asymptomatic foot,
whereas extravascular fluorescence is observed in the sole of the symp-
tomatic foot (Figure 6C ). Figure 6D shows both legs of a subject who
was clinically diagnosed with unilateral LE of the right leg after right
inguinal lymph node dissection. Whereas the asymptomatic leg shows
some lymphatic structure, both legs have extensive regions of extra-
vascular fluorescence, which may be indicative of undiagnosed, subclin-
ical lymphedema in the asymptomatic limb. The bright signal outside
the limb tracing in Figure 6, A and C , is due primarily to reflection
of the bright fluorescent signal, generated by extravascular ICG, off
the imaging bed and secondarily to excitation light leakage.
Of the 10 unilateral leg LE cases investigated, 2 subjects had no
observed lymph contractile function in the symptomatic limb. As
shown in Table 2, the mean ± SD apparent velocities in the symp-
tomatic and asymptomatic legs were 0.8 ± 0.4 and 0.8 ± 0.5 cm/sec,
respectively, and the mean ± SD periods were 72.1 ± 45.1 and 65.3 ±
46.4 seconds, respectively. On average, 6 ± 13 more packets were seen
in the asymptomatic legs than in the contralateral symptomatic legs.
The overall propulsion rates were 0.3 ± 0.2 and 0.2 ± 0.2 propulsions
per minute for the asymptomatic and symptomatic legs, respectively,
as shown in Table 2.
Overall Propulsion Rate
Our linear statistical models indicate that diagnosis and limb have a
significant effect on the overall propulsion rate with P < .05 and P <
.0005, respectively. As shown in Table 2, the legs consistently have lower
mean propulsion rates compared with the arms, whereas both arms and
legs have lower mean propulsion rates in the symptomatic limbs. No
statistical impact due to side or dose was observed.
Discussion and Conclusions
In this study, we qualitatively and quantitatively compared architectural
and contractile functional differences between the lymphatics of con-
trol and clinically diagnosed unilateral LE subjects. Both primary and
secondary LE are chronic, progressive, and largely uncharacterized dis-
eases that our study sought to capture at one time point for comparison
to presumed “normal” control subjects. In addition, the cause of LE,
whether genetic or acquired, is in itself controversial because genetic
susceptibility for acquiring LE after surgery or trauma remains to be de-
termined. We are unaware whether the observed abnormal patterns of
lymphatic architecture and function in LE subjects existed before trauma
or before onset of symptoms. Nonetheless, by examining presumed
“normal” controls and clinically diagnosed LE subjects, we sought to
Figure 5. Lymphatic reflux. (A) A closer view of the lymph vessel with lymph reflux in the asymptomatic arm of subject LA03 seen in
Figure 4F (Video W3 for visualization). In this example, there appears to be insufficient valvular function allowing a portion of each for-
ward moving packet to drain back from ROI 2 (red) to ROI 1 (blue) as illustrated in (B) a three-dimensional plot of fluorescent intensity as
a function of time and distance. By following the intensity peaks, the direction of flow is determined. (C) Fluorescent intensity profiles at
ROIs 1 and 2.
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image key differences between normal lymphatic architecture and con-
tractile transport function and dysfunction using microgram amounts
of fluorescent contrast agent.
Lymphatic Architecture
The architectural characteristics of the lymphatic systems imaged in
the LE subjects are striking, not readily amendable for immediate quan-
titative analysis, and not generally seen in the control subjects, possibly
making them excellent diagnostic indicators of lymphatic disorders.
Extravascular accumulation of dye especially near the injection sites
(for examples, see Figure 4) seen in LE subjects may be attributed to
result from failure of initial lymphatic collection (as visualized in Chy+/−
animals studies with vascular endothelial growth factor receptor 3 mu-
tation [27]). It remains to be investigated why fluorescent networks of
lymphatic capillaries appear in distinct regions often distal to the site
of surgical trauma as in the asymptomatic arm of the double mastec-
tomy subject (Figure 4F). Architectural features of 1) extravascular dye
accumulation and 2) fluorescent capillary networks were only seen in
2 of 48 limbs of control subjects but were observed in all 20 symptom-
atic and 7 of 20 asymptomatic limbs of LE subjects. Of the seven sub-
jects with these features on the asymptomatic limb, two were diagnosed
with primary LE (no known trauma before onset), two developed
LE after insect bites, and three (two arms and one leg) developed LE
after surgery.
Tortuous vessels are prevalent in both symptomatic and asymp-
tomatic limbs of LE subjects (14/20) and were also visualized in 5 of
24 control subjects. It is unknown whether the presence of tortuous
vessels in otherwise normal-looking control subjects is 1) benign with
no prognostic indication, 2) indicative of an undiagnosed lymphatic
malformation or disorder that could portend complications after lym-
phatic assault, or 3) as suggested by some of the subject’s personal
accounts of prior medical history, associated with presumptive lym-
phangiogenesis related to prior injury or trauma. The role of the lym-
phatics in tissue repair mechanisms remains unknown.
Lymphatic Contractile Function
In the unilateral arm LE and control subjects studied, our statistical
models indicate that there is a significant contribution to the apparent
propagation velocities and periods by diagnosis and, in the case of pe-
riodicity, limb. However, the high variability of these measurements
may preclude classification of disease based on apparent propagation
velocity, period, or propulsion rate alone. Figure 7 presents whiskered
Figure 6. Comparison of architecture in symptomatic and asymptomatic legs. (A) Lower legs of a 23-year-old woman (subject LL05) with
lymphedema on the left leg (right in images). Asymptomatic limb looks normal, although it has a paucity of lymphatic vessels, whereas
the symptomatic limb has diffuse extravascular fluorescence with no distinct structure. (B) A closer look at the ankles of the same
subject as (A) shows that the asymptomatic limb has a tortuous vessel emanating from the injections site, whereas the symptomatic
limb shows diffuse extravascular fluorescence again with perhaps a large curved lymphatic vessel just above the ankle bone. (C) Image
illustrating the diffusion of dye into the symptomatic foot of the same subject. (D) Lower legs of a 65-year-old woman (subject LL10) with
clinically diagnosed lymphedema on the right leg (left in image). Both symptomatic and asymptomatic legs show extensive diffuse
extravascular fluorescence, although some structure is apparent in asymptomatic limb.
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box plots of the apparent velocity and period measurements as well
as the propulsion rate as functions of diagnosis and limb. The colored
dots illustrate the actual scatter of the measurements, whereas the black
dots indicate the presence of outliers. The lack of classifiable differences
seems to indicate that despite the disease status and/or the presence of
lymphatic abnormalities in the limb, the apparent propagation velocity
and period remain similar. The high variability of these quantities is
reflective of the complex and poorly understood physiology that regu-
lates lymphatic function. Perhaps as our understanding of the lym-
phatics improves, it may be possible to take into account the regulatory
physiology with other measurements such as hydration levels or trans-
mural pressure to accomplish diagnostic, quantitative, NIR fluorescence
lymphatic imaging.
More propulsion events were consistently observed in control and
asymptomatic limbs than symptomatic limbs but again the large variabil-
ity may prevent its use as a means to classify disease. The lower propul-
sion rates observed in symptomatic limbs may be due to the tendency
to visualize fewer functional lymphatic vessels compared with control
and asymptomatic limbs resulting in a net reduction of lymph transport
to draining nodal basins as commonly seen in lymphoscintigraphy.
We observed backward propagation of the fluorescent signal in the
asymptomatic arm of a breast cancer–related LE subject (LA03; Fig-
ures 4F and 5 and Video W3) and in the legs of two control subjects
(CL04 and CL05) that is a result of lymphatic reflux and could be
attributed to lymph valvular insufficiency or to retrograde propagation
of lymphatic contractions as has been documented previously in in situ
studies of rats [28]. Whether the backward propagation or reflux ex-
isted in the lymphedema subjects before surgical insult and/or portends
the development of LE remains to be evaluated in longitudinal studies
of subjects undergoing nodal dissections.
Images of deeper lymphatics, such those seen in the back of the knee
(Figure 3C), the thigh (Figure 3D), and the upper arm (top of Figure 1C ),
often are not as well focused as the lymphatics seen in the hands and feet.
This broadening of the structure is due to the scatter the fluorescent sig-
nal experiences as it propagates from the lymphatics to the surface of the
skin. Scatter and absorption of photons will likely limit the ability to non-
invasively image lymphatic structure deeper than several centimeters with
our imaging system. However, efforts are underway to develop three-
dimensional fluorescence tomography systems that may be able to resolve
deeper lymphatics. Whereas penetration depth is an issue with fluores-
cence imaging because of the physics of light propagation in tissue, this
study and that of others (see Marshall et al. [19] for a review of lymphatic
imaging with ICG) illustrate the potential of NIR fluorescent imaging to
further our understanding of the lymphatics and its spectrum of disease.
In conclusion, in this feasibility study, we have demonstrated the
ability to noninvasively interrogate healthy and diseased human lym-
phatics in vivo using microdose injections of ICG and NIR fluorescence
imaging. Our ability to see real-time contractile function in health and
disease using microgram doses of contrast agent is a result of the in-
creased sensitivity of our instrument compared with other NIR fluo-
rescence imagers found in the literature [19]. The lack of literature on
NIR fluorescence imaging of real-time contractile lymphatic function
may indicate that 1) existing imaging systems do not have the neces-
sary sensitivity owing to high amounts of excitation light leakage and/
or 2) the administration of milligram amounts of ICG may inhibit its
visualization by “saturating” the lymphatic vessels with fluorophore,
preventing subtle variations in fluorophore concentration or volume
from being imaged. The ability to visualize microgram amounts of
contrast agents also presents the opportunity to introduce new first-
in-human agents under the reduced safety and toxicity requirements
of microdosing [29].
Although quantitative functional differences of apparent propagation
velocity and period were too subtle to classify individual lymphatic dis-
ease in this phase 0 trial, NIR fluorescence provided exquisite informa-
tion on lymphatic architecture and may provide a much needed tool
to enhance our understanding of lymphovascular disease and may
potentially aid in diagnosing and phenotyping lymphatic disease for
determining cancer patient susceptibility to postsurgical lymphatic com-
plications. Our observations of lymphatic phenotypes in asymptomatic
arms and legs may indicate subclinical disease and warrant further inves-
tigation. Recent NIR fluorescent imaging data [30] showing initial loss
of contractile function and extensive remodeling of lymphatic architec-
ture in association with cancer metastasis in animals suggest the use of
NIR fluorescence imaging to 1) not only detect the early stages of cancer
Figure 7. Box plots of (A) apparent propagation velocity, (B) period, and (C) propulsion rate as a function of limb and diagnosis. Also shown
is the measurement jitter (colored dots) that illustrates the magnitude of all measurements made and the outliers (black dots).
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metastasis in humans but also perhaps to 2) provide an early end point,
showing inhibition or regression of lymphangiogenesis in response to
these emerging antimetastasis therapeutics.
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Table W1. Summary of Demographics, Dosage, Apparent Contractile Propagation Velocity, and Period in Control Arm Subjects.
Subject ID Age Sex Ethnicity* Dose
ICG (μg)
Side Apparent Propagation Velocity (mm/s) Period (sec)
No. Velocity
Measurements
Range Median Mean ± SD No. Period
Measurements
Range Median Mean ± SD
CA01 46 F C 375 Left 23 0.4-2.7 0.7 0.9 ± 0.5 12 9-66 36.5 39.1 ± 19.2
Right 19 0.3-1.0 0.8 0.7 ± 0.2 14 15-65 20.0 24.3 ± 12.3
CA02 59 M C 375 Left 18 0.3-2.6 0.7 0.9 ± 0.6 9 12.6-62.9 17.8 23.6 ± 16.0
Right 42 0.3-2.6 0.7 0.8 ± 0.5 23 11.0-39.7 23.9 23.1 ± 8.9
CA03 22 M C 200 Left 135 0.3-2.6 0.9 0.9 ± 0.3 57 3.4-117.1 42.2 48.6 ± 27.9
Right 105 0.4-4.9 0.9 1.0 ± 0.6 31 9.5-81.4 30.3 33.8 ± 19.7
CA04 41 F C 200 Left 36 0.4-2.5 1.0 1.2 ± 0.5 11 15.0-82.6 56.4 48.6 ± 23.7
Right 87 0.3-3.1 0.8 0.9 ± 0.4 32 8.9-138.2 25.7 41.0 ± 35.1
CA05 46 F C 200 Left 32 0.4-2.1 0.8 0.9 ± 0.4 13 3.5-199.6 47.0 60.0 ± 53.4
Right 46 0.4-1.8 0.8 0.9 ± 0.3 11 10.5-43.1 29.1 29.2 ± 11.2
CA06 50 F AA 200 Left† 47 0.4-1.3 0.8 0.8 ± 0.2 34 18.5-157.7 28.6 32.9 ± 23.2
Right 105 0.3-1.1 0.8 0.8 ± 0.2 75 7.7-106.1 22.8 27.1 ± 15.4
CA07 36 F C 200 Left 112 0.2-4.3 0.9 0.9 ± 0.5 53 2.3-85.0 29.5 32.5 ± 18.7
Right 36 0.3-2.3 0.8 0.9 ± 0.4 18 12.5-116.7 74.6 67.1 ± 36.4
CA08 48 F C 200 Left 37 0.3-1.6 0.7 0.8 ± 0.3 10 7.7-133.0 42.2 56.8 ± 45.7
Right 75 0.4-1.7 0.8 0.8 ± 0.2 42 9.3-173.4 40.1 47.8 ± 35.8
CA09 35 F AA 200 Left 12 0.2-0.7 0.4 0.4 ± 0.2 3 41.0-54.8 45.2 47.0 ± 7.1
Right 15 0.2-0.8 0.5 0.5 ± 0.1 6 30.5-57.4 39.8 42.5 ± 11.8
CA10 41 F H 300 Left 61 0.2-2.4 0.7 0.8 ± 0.4 33 13.1-77.9 30.3 33.3 ± 13.4
Right 48 0.1-1.5 0.9 0.8 ± 0.3 28 15.8-71.5 26.4 31.7 ± 13.4
CA11 35 F C 300 Left 21 0.3-1.1 0.5 0.6 ± 0.2 15 27.0-208.9 55.4 64.9 ± 47.0
Right 131 0.2-1.0 0.6 0.6 ± 0.1 107 16.1-188.7 36.7 46.5 ± 28.2
CA12 37 M A 300 Left 75 0.4-1.0 0.6 0.6 ± 0.1 51 7.0-205.1 71.3 78.1 ± 48.9
Right 175 0.1-1.2 0.5 0.6 ± 0.2 115 9.0-250.5 77.7 82.0 ± 46.6
*A indicates Asian; AA, African American; C, Caucasian; and H, Hispanic.
†Observed tortuous vessel (T).
Table W2. Summary of Demographics, Dosage, Apparent Contractile Propagation Velocity, and Period in Control Leg Subjects.
Subject ID Age Sex Ethnicity* Dose
ICG (μg)
Side† Features‡ Apparent Propagation Velocity (cm/sec) Period (sec)
No. Velocity
Measurements
Range Median Mean ± SD No. Period
Measurements
Range Median Mean ± SD
CL01 46 F C 400 Left T 44 0.3-2.7 0.8 1.0 ± 0.6 20 15-93 30.5 38.1 ± 21.9
Right — 36 0.3-1.6 0.9 0.9 ± 0.3 22 7-167 69.0 69.5 ± 38.2
CL02 23 M C 262.5 Left — 27 0.6-6.1 1.9 2.2 ± 1.4 16 7.6-153.9 13.8 40.5 ± 47.6
Right — 8 0.8-1.8 1.3 1.3 ± 0.4 0 — — —
CL03 29 F C 400 Left — 45 0.3-1.4 0.6 0.7 ± 0.3 10 31.4-118.2 45.6 63.6 ± 33.1
Right — 42 0.3-1.9 0.7 0.8 ± 0.4 15 14.2-95.1 46.3 49.1 ± 24.7
CL04 27 F C 350 Left — 68 0.4-3.2 0.9 1.1 ± 0.6 16 9.6-169.0 63.1 70.3 ± 40.1
Left,
Back
R 1 −1.5 −1.5 — 0 — — —
Right — 15 0.3-1.6 0.8 0.8 ± 0.4 1 78.3 78.3 —
CL05 29 F C 375 Left — 29 0.5-2.0 0.8 0.9 ± 0.4 6 41.2-110.6 57.9 65.1 ± 27.7
Left,
Back
R 1 −0.4 −0.4 — 0 — — —
Right T 23 0.5-1.4 0.7 0.8 ± 0.3 5 15.5-97.5 57.5 52.0 ± 31.2
CL06 35 F C 400 Left — 5 0.8-1.2 0.9 1.0-0.2 0 — — —
Right — 19 0.3-2.1 0.8 1.0 ± 0.5 7 15.9-85.3 28.5 39.7 ± 25.1
CL07 52 F C 350 Left T 53 0.2-2.4 0.7 0.8 ± 0.4 17 10.3-96.6 20.9 33.4 ± 28.6
Right EF 45 0.2-1.2 0.6 0.6 ± 0.3 22 10.1-132.3 35.9 40.4 ± 27.7
CL08 40 F A 400 Left — 35 0.2-2.3 0.6 0.7 ± 0.4 15 6.9-125.0 33.2 35.1 ± 27.9
Right — 45 0.3-1.9 0.6 0.8 ± 0.4 29 13.8-110.2 33.9 42.1 ± 24.0
CL09 25 F C 400 Left — 42 0.2-2.5 0.8 1.1 ± 0.7 21 3.2-193.8 82.4 78.1 ± 54.6
Right — 3 0.3-1.1 0.7 0.7 ± 0.4 0 — — —
CL10 34 F C 400 Left — 20 0.4-1.4 0.9 0.9 ± 0.2 12 12.3-125.4 78.4 77.0 ± 37.5
Right — 17 0.3-1.8 0.8 0.9 ± 0.5 5 32.5-110.3 51.3 64.3 ± 34.9
CL11 22 M C 400 Left T, H 30 0.1-1.7 0.8 0.7 ± 0.4 10 27.6-107.4 58.0 58.5 ± 23.5
Right — 12 0.4-1.3 1.0 0.9 ± 0.3 3 50.0-107.0 55.4 70.8 ± 31.5
CL12 59 F C 400 Left — 36 0.4-2.7 0.9 1.0 ± 0.5 12 28.3-83.3 40.5 44.3 ± 15.4
Right — 33 0.1-11.7 1.0 1.4 ± 2.0 9 4.8-152.6 31.9 43.9 ± 46.5
*A indicates Asian; AA, African American; C, Caucasian; and H, Hispanic.
†Back = Backward movement.
‡Features noted include tortuous vessels (T), hyperplastic lymphatic networks (H), extravascular fluorescence (EF), and reflux or retrograde propagation (R).
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Video W1. Movie of the injection, uptake, and subsequent pro-
pulsion of ICG from the injection sites in the foot toward the draining
lymph nodes. This movie, although not of high quality because of
the movement of the foot, illustrates the similarity of the dye front
propagation immediately after ICG administration and the propaga-
tion of the fluorescent packets within the lymphatics as observed in
Videos W2 and W3.
Video W2. Movie of active lymphatic propulsion in the right arm of
control subject CA10.Movie is approximately three times faster than
real time. Black square is covered injection site.
Video W3.Movie of active lymphatic propulsion from injection sites
in right foot of control subject CL09. Movie is approximately three
times faster than real time. Black squares are covered injection sites.
Figure W1. Magnified fluorescent images of the lymphatic malformations seen in the asymptomatic arm of subject LA03 illustrating
the dense fluorescent capillary networks and tortuous vessels near the (A) injection sites in the wrist and (B) in the upper arm distal to all
injection sites.
Video W4. Movie of lymphatic reflux in asymptomatic arm of sub-
ject LA03. Note the backward movement of fluorescence after each
forward propulsion event. Movie is approximately three times faster
than real time. Black squares are covered injection sites.
Figure W2. Magnified fluorescent images of the tortuous lymphatic vessels seen in the asymptomatic ankle (subject LL05) on both the
(A) medial and (B) lateral sides.
